Patents Assigned to Schering Aktiengesellschaft
  • Patent number: 7220856
    Abstract: The present invention relates to CCR5 receptor antagonists of formulae (1a) or (1b): enantiomers, diastereomers, salts and solvates thereof wherein R1, R2, R3, R4, R5, and R7 are as defined herein. The invention further includes a method of CCR5-mediated disorders employing such compounds.
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: May 22, 2007
    Assignee: Schering Aktiengesellschaft
    Inventors: Laura Dunning, Stefan Jaroch, Monica J. Kochanny, Wheeseong Lee, Xiongdong Lian, Meina Liang, Shou-Fu Lu, James Onuffer, Gary Phillips, Guo-Ping Wei, Bin Ye
  • Publication number: 20070105949
    Abstract: This invention is directed to compounds useful as intermediates in the synthesis of lipoxin A4 analogs of the following formulas (I) and (II): wherein R1, R2, R3, R4 and R5 are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also useful in treating pulmonary or respiratory tract inflammation in humans.
    Type: Application
    Filed: November 3, 2006
    Publication date: May 10, 2007
    Applicant: Schering Aktiengesellschaft
    Inventors: Danja Grossbach, William Guilford, Michael Sander
  • Patent number: 7211241
    Abstract: Described are new cascade polymer complexes, compositions containing them and use of the complexes in diagnosis and therapy, particularly for magnetic resonance imaging and computer tomography imaging.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: May 1, 2007
    Assignee: Schering Aktiengesellschaft
    Inventors: Heribert Schmitt-Willich, Johannes Platzek, Bernd Radüchel, Andreas Mühler, Thomas Frenzel
  • Patent number: 7211680
    Abstract: Compounds of Formula I, wherein Y1, Y2, R1–R6, Q and Z are as defined herein, are vitamin D derivatives. These compounds are useful for, e.g., the treatment hyperprolifierative diseases of the skin, tumor diseases and precancerous stages, auto-immune diseases, rejection reactions in the case of autologous, allogenic or xenogenic transplants, AIDS, atopic skin conditions, secondary hyperparathyroidism, renal osteodystrophia, senile and postmenopausal osteoporosis, diabetes mellitus type II, degenerative diseases of the peripheral and central nervous system, hypercalcemias, granulomatous diseases, paraneoplastic hypercalcemias, hypercalcemias in hyperparathyroidism, hirsutism, ateriosclerosis, and/or inflammatory diseases.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: May 1, 2007
    Assignee: Schering Aktiengesellschaft
    Inventors: Andreas Steinmeyer, Gerald Kirsch, Guenter Neef, Katiea Schwarz, Ruth Thieroff-Ekerdt, Herbert Wiesinger, Martin Haberey, Marianne Fahnrich
  • Patent number: 7208140
    Abstract: The metal complexes of general formula I in which Hal stands for bromine or iodine and A1 and A2 have different meanings, are suitable as contrast media.
    Type: Grant
    Filed: February 19, 2004
    Date of Patent: April 24, 2007
    Assignee: Schering Aktiengesellschaft
    Inventors: Heiko Schirmer, Hanns-Joachim Weinmann, Johannes Platzek, Jose Luis Martin, Juan R. Harto, Bjoern Riefke
  • Patent number: 7202263
    Abstract: N-Heterocyclic derivatives of the following formula: where m, n, p, A1, R1, R2, R3 and R4 are described herein, as well as other N-heterocyclic derivatives, are useful as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: April 10, 2007
    Assignee: Schering Aktiengesellschaft
    Inventors: David Davey, Raju Mohan, Gary Phillips, Guo Ping Wei, Wei Xu
  • Publication number: 20070078262
    Abstract: The present invention relates to thiomorpholino steroid compounds of general formula I, which may advantageously be employed to stimulate meiosis in human oocytes, the steroid being specifically characterized by a thiomorpholino moiety bonded to C17 of the steroid skeleton via an alkylen spacer.
    Type: Application
    Filed: July 13, 2004
    Publication date: April 5, 2007
    Applicant: SCHERING AKTIENGESELLSCHAFT
    Inventors: Thorsten Blume, Bernhard Lindenthal, Katja Prelle, Michaele Peters-Kottig
  • Patent number: 7199268
    Abstract: A new process for the production of dendritic trimesic acid triamides is described.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: April 3, 2007
    Assignee: Schering Aktiengesellschaft
    Inventors: Johannes Platzek, Klaus-Dieter Graske
  • Patent number: 7199146
    Abstract: A compound is disclosed, which is useful in treating a mammal having a disease-state characterized by thrombotic activity. The compound is of the following formula: wherein A, B, R1, R2, R3 and R4 are as defined herein or an isomer or isomeric mixture thereof or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 22, 2006
    Date of Patent: April 3, 2007
    Assignee: Schering Aktiengesellschaft
    Inventors: Damian O. Arnaiz, Yuo-Ling Chou, Brian Griedel, Raju Mohan, Kenneth J. Shaw
  • Publication number: 20070049583
    Abstract: Compounds of formula (I), their tautomeric and isomeric forms and salts, as well as the process for their production and their use in pharmaceutical compositions, are described.
    Type: Application
    Filed: October 25, 2006
    Publication date: March 1, 2007
    Applicant: Schering Aktiengesellschaft
    Inventors: Peter Holscher, Hartmut Rehwinkel, Stefan Jaroch, Detlev Sulzle, Margrit Hillmann, Gerardine Burton, Fiona McDonald
  • Publication number: 20070037864
    Abstract: This invention is directed to lipoxin A4 analogs of the following formula (I) and (II): wherein R1, R2, R3, R4 and R5 are described herein. These analogs are useful in treating inflammatory and autoimmune disorders in humans. These analogs are also useful in treating pulmonary or respiratory tract inflammation in humans.
    Type: Application
    Filed: October 23, 2006
    Publication date: February 15, 2007
    Applicant: Schering Aktiengesellschaft
    Inventors: John Bauman, William Guilford, John Parkinson, Werner Skuballa, Babu Subramanyam
  • Patent number: 7176013
    Abstract: This invention relates to novel modified corin molecules, or fragments or derivatives thereof, comprising a substitute activation sequence. The modified corin molecules are cleaved at the substitute activation sequence, thereby generating activated corin molecules, or fragments or derivatives thereof, that exhibit the functional activity of naturally occurring, wild-type corin molecules. The modified corin molecules can be used to treat a variety of diseases or disorders, including congestive heart failure and acute myocardial infarction.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: February 13, 2007
    Assignee: Schering Aktiengesellschaft
    Inventor: Qingyu Wu
  • Patent number: 7176207
    Abstract: Compounds of the following formula (I): where A, a, b, R1, R2, R3, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: February 13, 2007
    Assignee: Schering Aktiengesellschaft
    Inventors: Judi A Bryant, Brad O Buckman, Imadul Islam, Raju Mohan, Michael M Morrissey, Robert Guo-Ping Wei, Wei Xu, Shendong Yuan
  • Patent number: 7166592
    Abstract: Compounds of Formula 1 are useful in the treatment of inflammation.
    Type: Grant
    Filed: June 24, 2004
    Date of Patent: January 23, 2007
    Assignee: Schering Aktiengesellschaft
    Inventors: Stefan Jaroch, Manfred Lehmann, Norbert Schmees, Bernd Buchmann, Harmur Rehwinkel, Peter Droescher, Werner Skuballa, Konrad Krolikiewicz, Hartwig Hennekes, Heike Schaecke, Arndr Schottelius
  • Publication number: 20060292609
    Abstract: The present invention provides an improved, expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule in the cells of a subject, for use in the treatment of disease. In particular, the present invention provides an improved, regulated gene expression system, and pharmaceutical compositions and uses thereof for treatment of disease.
    Type: Application
    Filed: May 18, 2006
    Publication date: December 28, 2006
    Applicant: Schering Aktiengesellschaft
    Inventors: Maxine Bauzon, Richard Harkins, Terry Hermiston, Peter Kretschmer, Paul Szymanski
  • Publication number: 20060292074
    Abstract: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against a Tomoregulin (TR) polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.
    Type: Application
    Filed: June 23, 2006
    Publication date: December 28, 2006
    Applicant: Schering Aktiengesellschaft
    Inventors: Tara Heitner, David Light, Bing Liu, Noboru Satozawa, Xiao-Yan Zhao
  • Publication number: 20060281703
    Abstract: The present invention provides an improved, expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule in the cells of a subject, for use in the treatment of disease. In particular, the present invention provides an improved, regulated gene expression system, and pharmaceutical compositions and uses thereof for treatment of disease.
    Type: Application
    Filed: May 18, 2006
    Publication date: December 14, 2006
    Applicant: Schering Aktiengesellschaft
    Inventors: Maxine Bauzon, Richard Harkins, Terry Hermiston, Peter Kretschmer, Paul Szymanski
  • Patent number: 7148207
    Abstract: This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: December 12, 2006
    Assignee: Schering Aktiengesellschaft
    Inventors: Wolfgang Heil, Ulf Tistam, Ralph Lipp, Johannes-Wilhelm Tack
  • Patent number: 7141566
    Abstract: The invention relates to compounds of formula (I), the tautomeric and isomeric forms and salts thereof, in addition to a method for production and use thereof in medicaments.
    Type: Grant
    Filed: August 23, 2000
    Date of Patent: November 28, 2006
    Assignee: Schering Aktiengesellschaft
    Inventors: Peter Hölscher, Hartmut Rehwinkel, Stefan Jaroch, Detlev Sülzle, Margrit Hillmann, Gerardine Anne Burton, Fiona Mcdougall McDonald
  • Patent number: 7138379
    Abstract: The present invention is directed towards a method of potentiating the anti-growth effects of type I interferon (IFN) on cells in a target cell population comprising increasing the number of functional IFNAR2c receptors on the surface of modified cells within the target cell population and then exposing the modified cells to a therapeutically effective amount of a type I IFN or by exposure to endogenously produced IFN.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: November 21, 2006
    Assignee: Schering Aktiengesellschaft
    Inventors: Ed Croze, David Vogel, Dean Russell-Harde